Reviva prices $18M public offering of 12M shares and warrants

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Offering of 12M shares of common stock plus Series A warrants (6M shares, 6-month term) and Series B warrants (12M shares, 5-year term) at $1.50/unit.
Gross proceeds $18M; net proceeds ~$15.8M after underwriting discounts and expenses.
Series A warrants exercisable at $1.50, expire in 6 months; Series B warrants at $1.50, expire in 5 years.
Expected closing on December 18, 2024; Citizens JMP Securities is sole bookrunner.
Proceeds to fund R&D, working capital, and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.